BeiGene Ownership
| BGNE Stock | USD 215.00 8.84 4.29% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 105 M | Current Value 106 M | Avarage Shares Outstanding 68.9 M | Quarterly Volatility 32.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
BeiGene |
BeiGene Stock Ownership Analysis
About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 8.19. BeiGene had not issued any dividends in recent years. BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Beigene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8600 people. For more info on BeiGene please contact John Oyler at 345-949-4123 or go to https://www.beigene.com.Besides selling stocks to institutional investors, BeiGene also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different BeiGene's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align BeiGene's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
BeiGene Quarterly Liabilities And Stockholders Equity |
|
BeiGene Insider Trades History
About 19.0% of BeiGene are currently held by insiders. Unlike BeiGene's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against BeiGene's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of BeiGene's insider trades
BeiGene Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BeiGene is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BeiGene backward and forwards among themselves. BeiGene's institutional investor refers to the entity that pools money to purchase BeiGene's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Boxer Capital Llc | 2024-09-30 | 500 K | Public Investment Fund | 2024-06-30 | 354.4 K | Vestal Point Capital Lp | 2024-06-30 | 350 K | Artal Group S A | 2024-06-30 | 303.4 K | Bank Of America Corp | 2024-06-30 | 287.3 K | Baird Financial Group, Inc. | 2024-09-30 | 287.1 K | First Trust Advisors L.p. | 2024-06-30 | 250.4 K | Paradigm Biocapital Advisors Lp | 2024-09-30 | 200.3 K | Artisan Partners Limited Partnership | 2024-09-30 | 199.8 K | Baker Bros Advisors Lp | 2024-09-30 | 10.6 M | Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 6.4 M |
BeiGene Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BeiGene insiders, such as employees or executives, is commonly permitted as long as it does not rely on BeiGene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BeiGene insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BeiGene Outstanding Bonds
BeiGene issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BeiGene uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BeiGene bonds can be classified according to their maturity, which is the date when BeiGene has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
BeiGene Corporate Filings
F4 | 29th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 19th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify | |
F3 | 24th of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.19) | Revenue Per Share 225.239 | Quarterly Revenue Growth 0.395 | Return On Assets (0.1) | Return On Equity (0.23) |
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.